Update on subject-matter eligibility at the EPO and USPTO for life sciences

Audience

Fellows & Students 

Event information

Update on subject-matter eligibility at the EPO and USPTO for life sciences
Start date Thursday, April 15, 2021 02:00 PM
End date Thursday, April 15, 2021 03:00 PM
Price Non Member £73.20 (Includes £12.20 VAT)
Member £0.00 (Includes £0.00 VAT)

Synopsis

Subject-matter eligibility for life sciences inventions is an ongoing concern among applicants seeking patent protection at the USPTO. Claims that are granted in line with the USPTO guidelines for subject-matter eligibility can still fall for this same ground at the Federal Circuit. Happily, subject-matter eligibility is less controversial at the EPO. However, problems can arise when applicants try to file an EPO drafted application at the USPTO, and vice versa. In this webinar, we will look at recent updates in the case law, current USPTO guidance on Section 101, and strategies for balancing the (sometimes conflicting) requirements of the EPO and USPTO. 
Amanda Murphy circle.png

Amanda K. Murphy, Ph.D.

Amanda is a partner in Finnegan’s Washington DC office, and focuses her practice on strategic client counseling, portfolio management, and patent prosecution for a range of clients, including small startup companies, research foundations, and large biotechnology and pharmaceutical companies.

VB circle.png

K. Victoria Barker, Ph.D. 

Victoria is an associate in Finnegan’s London office, with experience in all areas of patent portfolio management from drafting and filing applications to prosecution strategy and beyond to EPO opposition and appeal procedures. Victoria’s experience spans a broad range of chemical technologies and key jurisdictions including China, Japan, and Korea.